AcelRx Pharmaceuticals Inc (ACRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Vincent J. Angotti
Employees:
40
351 GALVESTON DRIVE, REDWOOD CITY, CA 94063
650-216-3500

AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet. ZALVISO is a pre-programmed and patient-controlled analgesia system.

Data derived from most recent annual or quarterly report
Market Cap 8.12 Million Shares Outstanding7.449 Million Avg 30-day Volume 141.678 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.14
Price to Revenue2.0767 Debt to Equity0.233 EBITDA-27.533 Million
Price to Book Value0.3364 Operating Margin-1393.6281 Enterprise Value-5.244 Million
Current Ratio1.834 EPS Growth0 Quick Ratio1.411
1 Yr BETA -2.5234 52-week High/Low 4.59 / 0.18 Profit Margin-1486.5626
Operating Cash Flow Growth24.5354 Altman Z-Score-26.1744 Free Cash Flow to Firm -101.158 Million
Earnings Report2023-08-10
View SEC Filings from ACRX instead.

View recent insider trading info

AcelRx Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ACRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-06 by DASU BADRI N
  • 4: filed on 2023-03-06 by PALMER PAMELA P
  • 4: filed on 2023-03-06 by ASADORIAN RAFFI
  • 4: filed on 2023-03-06 by ANGOTTI VINCENT J.
  • 4: filed on 2023-02-14 by DASU BADRI N
  • 4: filed on 2023-02-08 by DASU BADRI N
  • 4: filed on 2023-02-08 by ASADORIAN RAFFI
  • 4: filed on 2023-02-08 by PALMER PAMELA P
  • 4: filed on 2023-02-08 by ANGOTTI VINCENT J.
  • 4: filed on 2022-07-15 by BROADFOOT JILL MARIE

    • Events (8k)

  • 8-K: filed on 2023-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-07:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-05:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2022-10-25:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-23:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-08-12:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DASU BADRI N CHIEF ENGINEERING OFFICER

    • Officer
    		 18,771 2023-03-03 3

    PALMER PAMELA P CHIEF MEDICAL OFFICER

    • Officer
    • Director
    		 43,315 2023-03-03 3

    ASADORIAN RAFFI CHIEF FINANCIAL OFFICER

    • Officer
    		 22,081 2023-03-03 3

    ANGOTTI VINCENT J. CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 63,836 2023-03-03 4

    HOFFMAN STEPHEN J

    • Director
    		 67,750 2022-07-15 1

    WAN MARK A

    • Director
    		 67,750 2022-07-15 1

    ADAMS ADRIAN

    • Director
    		 242,750 2022-07-15 1

    BROADFOOT JILL MARIE

    • Director
    		 61,500 2022-07-15 1

    ROSEN HOWARD B

    • Director
    		 125,250 2022-07-15 1

    AFABLE RICHARD

    • Director
    		 68,750 2022-07-15 1

    BOZILENKO MARINA

    • Director
    		 71,500 2022-07-15 1

    EDWARDS MARK G

    • Director
    		 281,250 2021-06-17 0

    HAMEL LAWRENCE G CHIEF DEVELOPMENT OFFICER

    • Officer
    		 157,564 2020-02-11 0

    HOFFMAN C STEVEN

    • Director
    		 0 2018-06-14 0

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS IV LP

    THREE ARCH PARTNERS III LP

    THREE ARCH ASSOCIATES IV LP

    THREE ARCH ASSOCIATES III LP

    • Director
    • 10% Owner
    		 0 2018-05-21 0

    SAIA JOHN G. GENERAL COUNSEL AND SECRETARY

    • Officer
    		 0 2018-04-16 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    		 No longer subject to file 2017-06-19 0

    MORRIS TIMOTHY E CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2017-02-07 0

    MITCHELL JANE WRIGHT CHIEF LEGAL OFFICER

    • Officer
    		 0 2017-02-07 0

    YATRA ONLINE, INC. CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2014-03-25 0

    SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P

    SKYLINE VENTURE MANAGEMENT IV, LLC

    FREUND JOHN GORDON

    KANEKO YASUNORI

    • 10% Owner
    • FORMER 10% HOLDER
    		No longer subject to file 2014-03-07 0

    KING RICHARD

    • Director
    		 134,567 2014-03-02 0

    WELCH JAMES H CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2014-02-04 0

    CHUNG DAVID CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2014-02-04 0

    NOHRA GUY P

    • Director
    		 2,507,974 2013-09-19 0

    SCHRECK THOMAS A

    • Director
    		 0 2012-07-24 0

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS III LP

    THREE ARCH ASSOCIATES III LP

    THREE ARCH PARTNERS L P

    THREE ARCH ASSOCIATES L P

    • Director
    • 10% Owner
    		 8,206,351 2012-05-29 0

    SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P

    SKYLINE VENTURE MANAGEMENT IV, LLC

    HOFFMAN STEPHEN J

    KANEKO YASUNORI

    FREUND JOHN GORDON

    • Director
    • 10% Owner
    		 4,418,161 2012-05-29 0

    THREE ARCH MANAGEMENT III LLC

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS III LP

    THREE ARCH ASSOCIATES III LP

    • Director
    • 10% Owner
    		 0 2011-02-16 0

    THREE ARCH MANAGEMENT IV, L.L.C.

    THREE ARCH ASSOCIATES IV LP

    WAN MARK A

    JAEGER WILFRED E

    THREE ARCH PARTNERS IV LP

    • Director
    • 10% Owner
    		 0 2011-02-16 0

    ACP IV, L.P.

    NOHRA GUY P

    JANNEY DANIEL

    DELEAGE JEAN

    MACK DAVID HENRY

    ACMP IV LLC

    • Director
    • 10% Owner
    		 8,177,073 2011-02-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 22:15:04 UTC -7.6694 12.7394 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 21:45:04 UTC -7.6694 12.7394 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 21:15:05 UTC -7.6694 12.7394 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 20:45:03 UTC -7.6694 12.7394 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 20:15:04 UTC -7.4271 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 19:45:03 UTC -7.4271 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 19:15:04 UTC -7.4271 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 18:45:03 UTC -7.4271 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 18:15:04 UTC -7.4271 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 17:45:04 UTC -7.4271 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 17:15:04 UTC -7.4271 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 16:45:04 UTC -7.4371 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 16:15:04 UTC -7.4371 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 15:45:03 UTC -7.4371 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 15:15:04 UTC -7.4371 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 14:45:04 UTC -7.4371 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 14:15:04 UTC -7.4371 12.4971 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 13:45:04 UTC -5.4358 10.4958 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 13:15:04 UTC -5.4358 10.4958 100000
    ACELRX PHARMACEUTICALS INC ACRX 2023-06-01 12:45:04 UTC -5.4358 10.4958 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ACRX -1070.0 shares, $-704.06 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments